Dec 27, 2010

Transition Therapeutics Announces Modification of the Collaboration Agreement for ELND005

Nov 30, 2010

Transition Therapeutics Announces Agreement Amendment

Nov 11, 2010

Transition Therapeutics Announces First Quarter Fiscal 2011 Financial Results

Nov 09, 2010

Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2011 Financial Results on Thursday, November 11th, at 4:30 P.M. EST

Sep 27, 2010

Transition Therapeutics Announces Fiscal 2010 Year End Financial Results

Sep 24, 2010

Transition Therapeutics to Hold Conference Call on Fiscal 2010 Year End Financial Results on Monday, September 27th, at 4:30 P.M. EST

Sep 17, 2010

Clinical Study of TT-223 in Combination With a GLP-1 Analogue Does Not Meet Study Efficacy Endpoints

Aug 09, 2010

Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study and Plans for Phase 3 for ELND005 (Scyllo-inositol)

Jun 30, 2010

Transition Therapeutics Announces Initiation of a Phase I Clinical Study of TT-301

Jun 07, 2010

Transition Therapeutics to Present at Investor Conferences

May 10, 2010

Transition Therapeutics Announces Third Quarter Fiscal 2010 Financial Results

May 10, 2010

Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2010 Financial Results on Tuesday, May 11th, at 8:30 A.M. EST

Mar 03, 2010

Transition Therapeutics Announces Licensing and Collaboration Agreement With Lilly

Feb 25, 2010

Transition Therapeutics to Present at Upcoming Conferences

Feb 10, 2010

Transition Therapeutics Announces Second Quarter Fiscal 2010 Financial Results

Feb 08, 2010

Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2010 Financial Results on Wednesday, February 10th, at 4:30 P.M. EST

Feb 05, 2010

Transition Therapeutics Announces Participation in 12th Annual BIO CEO & Investor Conference

Jan 25, 2010

Transition Therapeutics Announces Results of a Phase 2 Study of TT-223 in Type 2 Diabetes Patients